Health Canada submission follows international recommendations to develop monovalent XBB.1.5 COVID-19 vaccines Moderna is prepared to deliver updated COVID-19 vaccines in time for the fall 2023 vaccination season TORONTO – Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that it has initiated the filing of a rolling New Drug Submission (NDS) to Health Canada …